UK’s largest stock-market-listed firm weighs up Hong Kong or Shanghai listing to shield it from geopolitical tensions
AstraZeneca is considering spinning off its business in China and listing it in Hong Kong or Shanghai to shield the multinational drugmaker from geopolitical tensions.
Britain’s largest stock-market-listed company has drawn up the plans in attempt to protect its business from the fallout from increasing tensions between China and the US and its allies.
